MedPath

Prophylactic Norepinephrine and Phenylephrine Boluses for Postspinal Anesthesia Hypotension

Not Applicable
Completed
Conditions
Adverse Effect
Interventions
Registration Number
NCT05035888
Lead Sponsor
General Hospital of Ningxia Medical University
Brief Summary

The purpose of this study is to investigate the potency between prophylactic norepinephrine and phenylephrine boluses for postspinal anesthesia hypotension in patients undergoing caesarean section.

Detailed Description

Post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. The incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. Vasopressor has been highly recommended for routine prevention and/or treatment of post-spinal anesthesia hypotension. As a potential substitute drug for phenylephrine, norepinephrine has gradually been used in parturients undergoing cesarean section. There's some evidence that prophylactic infusion of norepinephrine could effectively reduce the incidence of post-spinal anesthesia hypotension in parturients undergoing cesarean section. However, few studies had been indicated the ED50 (prevent postspinal hypotension in 50% of patients) and ED90 of prophylactic norepinephrine bolus and its potency compared to phenylephrine for postspinal anesthesia hypotension in patients undergoing caesarean section. The purpose of this study is to investigate the potency between prophylactic norepinephrine and phenylephrine boluses for postspinal anesthesia hypotension in patients undergoing caesarean section.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
80
Inclusion Criteria
  • 18-45 years
  • Primipara or multipara
  • Singleton pregnancy ≥37 weeks
  • American Society of Anesthesiologists physical status classification I to II
  • Scheduled for cesarean section under spinal anesthesia
Exclusion Criteria
  • Body height < 150 cm
  • Body weight > 100 kg or body mass index (BMI) ≥ 40 kg/m2
  • Eclampsia or chronic hypertension or baseline blood pressure ≥180 mmHg
  • Hemoglobin < 7g/dl
  • Fetal distress, or known fetal developmental anomaly

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Norepinephrine groupNorepinephrineProphylactic norepinephrine bolus simultaneous with spinal anesthesia
Phenylephrine groupPhenylephrineProphylactic phenylephrine bolus simultaneous with spinal anesthesia
Primary Outcome Measures
NameTimeMethod
The dose that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients1-15 minutes after spinal anesthesia

Systolic blood pressure (SBP) \< 80% of the baseline

Secondary Outcome Measures
NameTimeMethod
The incidence of hypertension.1-15 minutes after spinal anesthesia

Systolic blood pressure (SBP) \>120% of the baseline.

The incidence of post-spinal anesthesia hypotension1-15 minutes after spinal anesthesia

Systolic blood pressure (SBP) \< 80% of the baseline

The incidence of nausea and vomiting.1-15 minutes after spinal anesthesia

Presence of nausea and vomiting in patients after spinal anesthesia

Partial pressure of oxygen (PO2)Immediately after delivery

From umbilical arterial blood gases.

The incidence of severe post-spinal anesthesia hypotension.1-15 minutes after spinal anesthesia

Systolic blood pressure (SBP) \< 60% of the baseline

The incidence of bradycardia.1-15 minutes after spinal anesthesia

Heart rate \< 60 beats/min.

pHImmediately after delivery

From umbilical arterial blood gases.

Base excess (BE)Immediately after delivery

From umbilical arterial blood gases.

APGAR score5 min after delivery

A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration

Trial Locations

Locations (1)

General Hospital of Ningxia Medical University

🇨🇳

Yinchuan, Ningxia, China

© Copyright 2025. All Rights Reserved by MedPath